The high prevalence and increasing incidence of obesity and associated cardiovascular risk emphasises the need to focus on obesity reduction in this high-risk population.

Metabolic syndrome (MetS) is the coexistence of obesity-related cardiovascular risk factors including hypertension, diabetes and dyslipidaemia. MetS is a precursor for atherosclerosis, including premature coronary artery disease, and cardiovascular mortality.

This educational hub has been supported by Boehringer Ingelheim. Boehringer Ingelheim has had no influence over the content. This educational hub is not intended for UK or IRELAND based physicians.

Close X
Other videos you might like

Recent Videos


ECO 23: Impact of Obesity on Heart Failure Outcomes

Laura Meems,

Watch time: 7m 7s

Video Series

e-SPACE Cardio-Renal-Metabolic 2023

Fausto J Pinto, John Spertus, , et al

Watch time: 16h 19m 46s (19 videos)


Obesity Management Strategies in 2023

Harold Bays,

Watch time: 17m 7s


EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients

Steven E Nissen,

Watch time: 7m 48s

Video Series

Dysphagia and the Management of Patients in Need of Lipid-Lowering

Watch time: 1h 7m 2s (4 videos)


SPLENDOR: Metabolic Surgery and Risk of MACE in NASH

Ali Aminian,

Watch time: 5m 41s